Shares of AbbVie ( ABBV 6.95%) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in ...
AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news ...
Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...
After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...
AbbVie stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm's fourth-quarter revenue exceeded ...
The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...
Sees Q1 revenue ~$12.8B, consensus $13.13B. Expects FX to have 1.6% negative impact on Q1 sales.Invest with Confidence: Follow TipRanks' Top ...
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.
Read about AbbVie, Novartis, ResMed and more in the latest Market Talks covering the Health Care sector.